Table 1 Baseline characteristics of 12-month MDS-UPDRS total progressors vs non-progressors.
From: Genetically-informed prediction of short-term Parkinson’s disease progression
Predictive feature | Progressors: Non-progressors (PPMI) | P-value | Progressors: Non-progressors (PDBP) | P-value |
|---|---|---|---|---|
Demographics | 64%: 36% | - | 48%:52% | - |
Sample size (n) | 529 | - | 350 | - |
Age (years) | 61.9 ± 0.5: 62.1 ± 0.61 | 0.033 | 59.4 ± 1.15: 60.0 ± 1.01 | 0.034 |
Sex (%F) | 24%: 22% | - | 60%: 73% | - |
Treatment status (%) | ||||
Levodopa | 14% ± 0.02: 19% ± 0.03 | 0.312 | 75% ± 0.03: 76% ± 0.03 | 0.856 |
Dopamine agonist | 10% ± 0.02: 13% ± 0.02 | 0.563 | 55% ± 0.04: 50% ± 0.04 | 0.434 |
Other PD medication | 14% ± 0.02: 18% ± 0.03 | 0.479 | 74% ± 0.03: 74% ± 0.03 | 0.932 |
Clinical instruments | ||||
MDS-UPDRS I | 4.1 ± 0.26: 4.6 ± 0.36 | 0.204 | 4.1 ± 0.39: 4.6 ± 0.43 | 0.566 |
MDS-UPDRS II | 3.5 ± 0.25: 4.2 ± 0.34 | 0.043 | 4.7 ± 0.5: 5.6 ± 0.56 | 0.355 |
MDS-UPDRS III | 15.9 ± 0.53: 21.0 ± 0.73 | <0.001 | 19.1 ± 0.94: 24.4 ± 1.05 | <0.001 |
MDS-UPDRS Total | 23.6 ± 0.8: 29.9 ± 1.07 | <0.001 | 28.0 ± 1.51: 34.8 ± 1.71 | 0.002 |
Hoehn & Yahr | 1.5 ± 0.03: 1.7 ± 0.04 | <0.001 | 2.03 ± 0.04: 2.1 ± 0.05 | 0.415 |
SE-ADL | 94.0 ± 0.42: 93.7 ± 0.52 | 0.478 | 88.5 ± 0.93: 87.4 ± 1.02 | 0.568 |
MoCA | 27.1 ± 0.15: 27.2 ± 0.2 | 0.013 | 26.0 ± 0.24: 26.1 ± 0.25 | 0.628 |
ESS | ||||
DaTScan neuroimaging | ||||
sbr_caudate_r | 2.1 ± 0.04: 2.0 ± 0.06 | 0.06 | - | - |
sbr_caudate_l | 2.1 ± 0.04: 2.0 ± 0.06 | 0.048 | - | - |
sbr_putamen_r | 0.9 ± 0.03: 0.9 ± 0.05 | 0.02 | - | - |
sbr_putamen_l | 0.9 ± 0.03: 0.9 ± 0.05 | 0.018 | - | - |
Genetics | ||||
Parkinson’s disease PRS (ave) | 0.004 ± 0.0: 0.005 ± 0.0 | 0.229 | 0.0026 ± 0.0: 0.0025 ± 0.0 | 0.534 |
Educational attainment PRS (ave) | 0.0005 ± 0.0: 0.0004 ± 0.0 | 0.594 | 0.0005 ± 0.0: 0.0004 ± 0.0 | 0.091 |
Monogenic risk (%) | 32%: 40% | - | 9%: 9% | - |
